A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) as an Adjunctive Treatment for Patients With Residual Schizophrenia.

Trial Profile

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) as an Adjunctive Treatment for Patients With Residual Schizophrenia.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Oct 2017

At a glance

  • Drugs Deudextromethorphan (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Sponsors Avanir Pharmaceuticals
  • Most Recent Events

    • 04 Oct 2017 Status changed from active, no longer recruiting to completed.
    • 17 May 2017 Planned End Date changed from 1 Oct 2017 to 1 Aug 2017.
    • 17 May 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top